Evaluating safety, efficacy of TP03 for Demodex blepharitis treatment

Elizabeth Yeu, MD, a cornea cataract and refractive surgeon at Virginia Eye Consultants shares results from the Saturn 1 pivotal phase 2b3 trial evaluating the safety and efficacy of a new investigational therapeutic from Tarsus Pharmaceuticals called TP03 (lotilaner ophthalmic solution 0.25%), for the treatment of patients diagnosed with Demodex blepharitis.